These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1740205)

  • 21. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization.
    Garcia JE; Padilla SL; Bayati J; Baramki TA
    Fertil Steril; 1990 Feb; 53(2):302-5. PubMed ID: 2105247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective study of short and long regimens of gonadotropin-releasing hormone agonist in in vitro fertilization program.
    Acharya U; Small J; Randall J; Hamilton M; Templeton A
    Fertil Steril; 1992 Apr; 57(4):815-8. PubMed ID: 1555693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, prospective trial of leuprolide acetate and conventional superovulation in first cycles of in vitro fertilization and gamete intrafallopian transfer.
    Kubik CJ; Guzick DS; Berga SL; Zeleznik AJ
    Fertil Steril; 1990 Nov; 54(5):836-41. PubMed ID: 2121551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments.
    Cummins JM; Yovich JM; Edirisinghe WR; Yovich JL
    J In Vitro Fert Embryo Transf; 1989 Dec; 6(6):345-52. PubMed ID: 2517507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrashort gonadotropin-releasing hormone agonist (GnRH-a) protocol in comparison with the long-acting GnRH-a protocol and menotropin alone.
    Ron-El R; Herman A; Golan A; Soffer Y; Nachum H; Caspi E
    Fertil Steril; 1992 Dec; 58(6):1164-8. PubMed ID: 1459267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The routine use of gonadotropin-releasing hormone agonists for all patients undergoing in vitro fertilization. Is there any medical advantage? A prospective randomized study.
    Kingsland C; Tan SL; Bickerton N; Mason B; Campbell S
    Fertil Steril; 1992 Apr; 57(4):804-9. PubMed ID: 1555691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed occurrence of an LH surge after HCG administration during ovarian stimulation with gonadotrophins: effect of LHRH treatment.
    Rojas FJ; Moretti-Rojas I; Balmaceda JP; Asch RH
    Hum Reprod; 1989 Aug; 4(6):643-6. PubMed ID: 2506219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success.
    Seifer DB; Thornton KL; DeCherney AH; Lavy G
    Fertil Steril; 1991 Sep; 56(3):500-4. PubMed ID: 1909977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization.
    Tan SL; Kingsland C; Campbell S; Mills C; Bradfield J; Alexander N; Yovich J; Jacobs HS
    Fertil Steril; 1992 Apr; 57(4):810-4. PubMed ID: 1555692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization.
    Katayama KP; Roesler M; Gunnarson C; Stehlik E; Jagusch S
    J In Vitro Fert Embryo Transf; 1988 Dec; 5(6):332-4. PubMed ID: 3146612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate.
    Sungurtekin U; Jansen RP
    Fertil Steril; 1995 Mar; 63(3):663-5. PubMed ID: 7851604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration do not predict outcome in assisted reproduction cycles.
    Givens CR; Schriock ED; Dandekar PV; Martin MC
    Fertil Steril; 1994 Nov; 62(5):1011-7. PubMed ID: 7926111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization.
    Imoedemhe DA; Sigue AB; Pacpaco EL; Olazo AB
    Fertil Steril; 1991 Feb; 55(2):328-32. PubMed ID: 1899396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjunctive leuprolide therapy does not improve cycle fecundity in controlled ovarian hyperstimulation and intrauterine insemination of subfertile women.
    Dodson WC; Walmer DK; Hughes CL; Yancy SE; Haney AF
    Obstet Gynecol; 1991 Aug; 78(2):187-90. PubMed ID: 1906152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition?
    Wada I; Matson PL; Troup SA; Morroll DR; Hunt L; Lieberman BA
    Br J Obstet Gynaecol; 1993 Mar; 100(3):265-9. PubMed ID: 8476833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of gonadotropin-releasing hormone agonist on embryo quality and pregnancy rate following cryopreservation.
    Benshushan A; Ezra Y; Simon A; Mordel N; Lewin A; Laufer N
    Fertil Steril; 1993 May; 59(5):1065-9. PubMed ID: 8486175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.